ESMO Congress 2024
In pursuing new products to help cancer patients see better outcomes, there are inherent, unique challenges and considerations. Customers leverage our experience, insights and capabilities—across clinical, medical affairs and commercial--every day to overcome these challenges and achieve more efficient oncology and hematology drug development.
Beyond solutions, Syneos Health aims to resonate with your goals. Whether it's understanding the nuances of current environmental challenges, delving deep into protocol development, or making sense of the dynamic investment landscape, we're here to collaborate, providing valuable insights and integrated solutions to shape the future of your oncology and hematology clinical trials.
Meet with Us
Join us at the ESMO World Congress (Booth #412) to explore how our collective wisdom and insights can be harnessed to tailor solutions to the specific requirements. Will you be attending ESMO 2024?
Our Attendees
Wouter Bartholomeus, MD
Executive Medical Director, Oncology & Hematology
Sheena Demelo, MD
Senior Medical Director
Patrick Kearns
Vice President. Business Development
Juliette Roberts
Vice President, Global Head, Oncology Therapeutic Strategy & Innovation
Register for Our Upcoming Webinar
Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer Care
October 4 | 11am ET
Related Content:
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Insights by Indication
Strategies for the Development of Anticancer Drugs in Japan: Exploring trends in anticancer drug development, requirements for approval and strategies for expediting these drugs to market in Japan.
Optimizing Go-to-Market Strategies for Oncology Product Launches in Europe: Experts examine a variety of go-to-market strategies, highlighting pros and cons of each, key geographic differentiators and strategic considerations for the European market.
Success Factors for Commercializing Cell and Gene Therapies: Examining cell and gene therapies, the commercial challenges that accompany them, and recommendations that can help manufacturers reach their commercial goals.
Our Capabilities
Oncology Expertise at all Levels
End-to-End Expertise in Early-Phase Oncology
Targeted Therapies for Solid-Tumors
